The U.S. Food and Drug Administration (FDA) has updated the warning label for the Depo-Provera birth control shot to include information about the risk of meningioma brain tumors. The label update is intended to warn doctors and patients that use of the Depo shot may be associated with the development of these tumors, particularly with longer or repeated use.
This FDA action comes as lawsuits involving Depo-Provera and meningioma brain tumors continue to move forward in courts across the country. Women who used Depo-Provera and were later diagnosed with meningioma or who are experiencing symptoms consistent with a brain tumor may now be questioning whether they were properly warned about these risks and whether they may qualify to file a lawsuit.
Women who were diagnosed with meningioma after using the Depo-Provera shot or who are concerned their symptoms may indicate a brain tumor can contact an experienced birth control attorney to find out more about their legal options or start the process of filing a claim.
What Is Depo-Provera?
Depo-Provera, also known as the Depo shot, is an injectable form of birth control containing medroxyprogesterone acetate, a synthetic hormone. The shot is typically administered once every three months and has been prescribed to millions of women in the United States over the past several decades.
While Depo-Provera has long been associated with side effects such as bone density loss, recent scientific research and regulatory scrutiny have raised concerns about its potential link to meningioma brain tumors.
What Is a Meningioma Brain Tumor?
A meningioma is a type of tumor that forms in the meninges, the protective membranes surrounding the brain and spinal cord. Although many meningiomas are classified as benign, they can still cause serious and life-altering symptoms due to their location and pressure on the brain.
Common meningioma symptoms may include:
- Persistent or worsening headaches
- Vision problems or vision loss
- Seizures
- Memory or cognitive difficulties
- Hearing loss or ringing in the ears
- Weakness or numbness in the arms or legs
- Personality or mood changes
In many cases, treatment for meningioma may require brain surgery, radiation therapy, or long-term medical monitoring.
FDA Warning Label Update for Depo-Provera
In late 2025, the FDA approved an update to Depo-Provera’s prescribing information to include new language about meningioma risk. The revised label alerts healthcare providers and patients that use of medroxyprogesterone acetate has been associated with the development of meningiomas.
According to the updated FDA labeling, patients receiving Depo-Provera should be monitored for symptoms that could indicate the presence of a brain tumor. The label also emphasizes the importance of counseling patients about potential risks, particularly for individuals who receive repeated injections over an extended period.
For many women, this update has raised an important question: Why were these risks not more clearly disclosed earlier?
Research Linking Depo-Provera to Meningioma
The FDA’s decision follows growing scientific evidence linking certain progestin medications, including medroxyprogesterone acetate, to an increased risk of intracranial meningiomas. Large observational studies have found higher rates of meningioma diagnoses among women who received injectable hormonal contraceptives compared to those who did not.
Meningiomas are known to be hormone-sensitive, meaning they may grow in response to hormonal stimulation. Researchers have identified progesterone receptors in many meningioma tumors, providing a biological explanation for how long-term exposure to synthetic hormones could contribute to tumor development.
Depo-Provera Lawsuits and Ongoing Litigation
As awareness of the meningioma risk has increased, women across the country have begun filing Depo-Provera brain tumor lawsuits against the drug’s manufacturer. These lawsuits generally allege that the manufacturer failed to adequately warn patients and doctors about the risk of meningioma associated with the birth control shot.
In August 2025, Reuters reported that the manufacturer argued in court filings that it could not have warned patients earlier due to federal drug-labeling requirements. Plaintiffs, however, contend that scientific evidence existed long before the FDA label update and that women were denied the opportunity to make fully informed decisions about their health.
The litigation continues to develop, and additional cases are expected as more women learn about the updated FDA warning.
Why the FDA Label Change Matters for Potential Lawsuits
FDA warning label updates are often cited in pharmaceutical litigation because they can demonstrate that a risk was significant enough to warrant formal disclosure. While the label change itself does not automatically prove wrongdoing, it may play an important role in claims that patients were not adequately informed of known or knowable risks.
For women diagnosed with meningioma after using Depo-Provera, the updated warning raises serious concerns about whether earlier warnings could have led to different contraceptive choices or earlier medical intervention.
Who May Qualify to File a Depo-Provera Meningioma Lawsuit?
Women who may be eligible to pursue a Depo-Provera meningioma lawsuit include those who:
- Received Depo-Provera injections for birth control
- Were diagnosed with a meningioma brain tumor
- Underwent brain surgery, radiation, or ongoing monitoring
- Experienced symptoms consistent with a brain tumor after Depo-Provera use
Each case is unique, and eligibility depends on factors such as duration of use, diagnosis, and medical history.
What Compensation May Be Available?
Depo-Provera lawsuits may seek compensation for damages such as:
- Medical expenses related to diagnosis and treatment
- Costs of brain surgery or radiation therapy
- Lost wages or reduced earning capacity
- Pain and suffering
- Long-term disability or reduced quality of life
An experienced attorney can help evaluate potential damages based on individual circumstances.
What Women Using Depo-Provera Can Do Now
Women who are currently using Depo-Provera or who used the shot in the past should pay close attention to symptoms that could indicate a meningioma. Anyone experiencing persistent headaches, vision changes, seizures, or neurological symptoms should seek medical evaluation.
Women who have already been diagnosed with a meningioma after using Depo-Provera may wish to speak with a lawyer experienced in pharmaceutical and birth control litigation to better understand their legal rights.
Contact an Experienced Depo-Provera Attorney
The FDA’s decision to update the Depo-Provera warning label marks a significant development for women’s health and for those affected by meningioma brain tumors.
If you or a loved one used Depo-Provera and were diagnosed with a meningioma – or are experiencing symptoms of a brain tumor – you may qualify to file a lawsuit.
An experienced Depo-Provera and meningioma attorney can review your case, explain your legal options, and help determine whether you may be eligible to seek compensation. Consultations are typically confidential, and many firms offer free case evaluations.
For more information about whether they may qualify to file a Depo-Provera lawsuit or to start the process of taking legal action today, women who used the birth control shot can contact a law firm with decades of experience in birth control litigation to receive a free legal consultation.
